Spironolactone Pediatric Dose — Diuretics
Spironolactone is a potassium-sparing diuretic that acts as a competitive aldosterone antagonist at the distal nephron, inhibiting sodium reabsorption and reducing potassium excretion. It is used in pediatric patients for conditions associated with fluid overload or secondary hyperaldosteronism, including heart failure, nephrotic syndrome, and chronic lung disease of prematurity. Its potassium-sparing properties make it a useful adjunct to loop or thiazide diuretics.
Pediatric Dosing
- Oral (PO): 1–3 mg/kg/day divided every 12 hours
The dose should be individualized based on clinical response, degree of fluid overload, and electrolyte status. Initiation at the lower end of the range (1 mg/kg/day) is appropriate in most settings, titrating upward as needed. Consult institutional protocol for maximum single or daily dose guidance, as the source does not specify an absolute ceiling.
Worked example: For a 10 kg child at 2 mg/kg/day: 10 × 2 mg/kg/day = 20 mg/day, administered as 10 mg every 12 hours.
Indications and Clinical Context
Spironolactone is indicated in pediatric patients requiring diuresis with potassium conservation, most commonly as part of a combination diuretic regimen in chronic heart failure (e.g., dilated cardiomyopathy, congenital heart disease with ventricular dysfunction) and in nephrotic syndrome with persistent edema. Its aldosterone-antagonist mechanism also provides antifibrotic and neurohormonal benefits that are particularly relevant in heart failure management.
In neonates and infants with chronic lung disease or bronchopulmonary dysplasia, spironolactone is frequently combined with a thiazide diuretic to minimize loop diuretic dependence and mitigate hypokalemia. Dosing should be guided by the clinical indication, patient age, and renal function, with reassessment as the clinical status evolves.
Administration and Monitoring
Spironolactone is administered orally and is available in tablet and compounded liquid formulations; consistent administration with food may improve absorption and tolerability. Because of its potassium-sparing mechanism, serum electrolytes — particularly potassium and sodium — should be monitored regularly, especially when co-administered with ACE inhibitors, ARBs, or potassium supplements, where the risk of hyperkalemia is increased.
- Route: Oral (PO) only per this dosing guidance
- Frequency: Divided every 12 hours
- Monitor: Serum potassium, sodium, renal function (BUN/creatinine), and blood pressure
- Key adverse effects: Hyperkalemia, gynecomastia with prolonged use, hyponatremia
- Use with caution in patients with renal impairment or anuria; consult institutional protocol for dose adjustments in reduced GFR
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.